Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries - Report - MDSpire
Advertisement
Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries
Clinical Report: Assessment of Pneumococcal Disease Impact in Children
Overview
This study estimates the clinical, economic, and societal burden of pneumococcal disease in children under 5 years old across five Latin American countries, highlighting the ongoing impact of serotypes not covered by existing vaccines. The findings indicate that higher-valent vaccines like PCV15 and PCV20 could significantly reduce this burden.
Background
Pneumococcal disease remains a leading cause of morbidity and mortality among children in Latin America, despite the introduction of pneumococcal conjugate vaccines (PCVs). The burden of disease caused by serotypes not included in the currently used PCVs necessitates the evaluation of higher-valent vaccines to enhance protection. Understanding the impact of these serotypes is crucial for public health strategies aimed at reducing pediatric pneumococcal disease.
Data Highlights
Country
Estimated Cases
Estimated Deaths
Economic Burden (USD)
Societal Burden (USD)
Five Latin American Countries
510,000
2,700
182 million
34 million
Key Findings
PCV20 serotypes are responsible for over 510,000 pneumococcal disease cases annually in the studied countries.
Approximately 2,700 deaths are attributed to these serotypes each year.
The total economic burden exceeds USD $182 million, with societal costs over USD $34 million.
Non-invasive diseases, particularly pneumonia and otitis media, account for the majority of the burden.
In countries using PCV10, a significant portion of the disease burden is due to serotypes included in PCV13 but not PCV10.
Serotypes unique to PCV20 contribute significantly to the remaining disease burden, especially in countries using PCV13.
Clinical Implications
The findings underscore the need for healthcare providers to consider the limitations of current PCVs and the potential benefits of higher-valent vaccines like PCV20. Implementing these vaccines could lead to a substantial reduction in both clinical cases and economic burden associated with pneumococcal disease in young children.
Conclusion
The study highlights the persistent burden of pneumococcal disease in Latin America despite existing vaccination efforts. Transitioning to higher-valent vaccines may be essential for further reducing this public health challenge.
by Sophie Warren, Rafael Bolanos, Lucila Rey-Ares, Juan Manuel Reyes, Jose Luis Huerta, Alana Ranzi, Rodrigo Fernandes Alexandre, Maria Gabriela Abalos, Liping Huang
